Favourable Response More Likely with Neoadjuvant Dual Immune Checkpoint Inhibitor Than with Anti-PD1 Therapy Alone, but the Occurrence of Adverse Events Is Also Higher
Findings from a pooled analysis of clinical trials conducted in patients with high-risk resectable melanoma